PAVmed (NASDAQ:PAVM) Raised to Strong-Buy at Lake Street Capital

PAVmed (NASDAQ:PAVM) was upgraded by stock analysts at Lake Street Capital to a “strong-buy” rating in a research report issued on Wednesday, Zacks.com reports.

PAVmed Stock Performance

NASDAQ PAVM opened at $1.88 on Wednesday. PAVmed has a one year low of $1.60 and a one year high of $9.00. The company has a 50-day simple moving average of $2.11 and a 200-day simple moving average of $2.81. The firm has a market capitalization of $17.73 million, a PE ratio of -0.21 and a beta of 0.83.

PAVmed (NASDAQ:PAVM) last posted its earnings results on Tuesday, March 26th. The company reported ($1.57) earnings per share (EPS) for the quarter. The business had revenue of $1.05 million for the quarter. Equities analysts forecast that PAVmed will post -5.69 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PAVmed stock. Raymond James & Associates raised its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 316.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,760 shares of the company’s stock after purchasing an additional 104,717 shares during the period. Raymond James & Associates owned 0.12% of PAVmed worth $41,000 at the end of the most recent quarter. 19.93% of the stock is owned by institutional investors.

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.